The trajectory of companies tied to the drug's legacy presents a complex investment scenario . While the initial boom generated substantial gains, generic competition have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a thorough assessment of intellectual property rights , evolving patient trends , and th